European pharma lobby says ‘non’ to French funding for off-label Avastin

Emily Wasserman The French government recently said "oui" to Roche's ($ RHHBY) cancer drug Avastin as a cheap, off-label treatment for the blinding eye disease wet age-related ...

UPDATED: Heard the latest Kite Pharma rumor? CEO says it ain’t so

John Carroll Kite CEO Arie Belldegrun has a simple message for investors this morning: Relax. FierceBiotech News

Novo says new U.S. plant may be best bet to offset the FX bite

Eric Palmer Novo Nordisk has forecast that currency hedging losses will leave it with an $ 850 million net loss for the year. But CEO Lars Rebien Sørensen thinks he may have ...

GSK says people and products were never in danger from Legionella bacteria in cooling towers

Eric Palmer GlaxoSmithKline says that the people and products at its manufacturing site in Zebulon, NC, were never in peril from the bacteria for Legionnaires' disease detected ...

Ackman’s ‘wolf pack’ drove Allergan into foreign hands, former CEO says

Carly Helfand Former Allergan CEO David Pyott and activist investor Bill Ackman called each other plenty of things during last year's months-long Valeant-Allergan takeover battle. ...

With solid Q2, Sanofi CEO says M&A could be part of growth strategy

Eric Palmer Sanofi's new CEO, Olivier Brandicourt, has a new company structure he is trotting out, a new potentially hot cholesterol-lowering drug to launch and now is able to take ...

With new cash on its way, it’s back to buying for deal-happy Allergan, CEO says

Carly Helfand On Monday, Allergan agreed to sell off a $ 40.5 billion piece of its business, inking a pact to exit the generics space with a sale to Teva Pharmaceutical Industries. ...

AbbVie falls short on Q2 sales–but don’t blame biosimilars, CEO says

Carly Helfand Huge sales leaps for AbbVie's Humira have been powering revenue forecast beats for the company in recent quarters. But this time, international sales of ...

As Bayer preps for its slim-down, a restructuring looms–but jobs are safe, CEO says

Carly Helfand As Bayer moves closer to hiving off its plastics businesses and becoming a life sciences-focused company, a restructuring is afoot, the company said Wednesday. But it's ...

Onglyza’s label should flag heart failure risks, FDA panel says

Tracy Staton AstraZeneca escaped the worst with an FDA panel vote on Onglyza. The agency's expert advisers almost unanimously backed the drug's cardiovascular safety. But the ...

PTC is trawling for a buyer with its risky DMD drug, Reuters says

Damian Garde PTC Therapeutics is looking to get bought, Reuters' sources say, betting that a larger company will covet its treatment for Duchenne muscular dystrophy enough to overlook ...

Lilly’s new insulin is likely DOA after latest delay, analyst says

Damian Garde Eli Lilly's already-delayed new insulin has run into another roadblock, as potentially harmful liver side effects have sent the company back to the clinic, putting ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS